Advertisement

 

 

Directional Migration in Esophageal Squamous Cell Carcinoma (ESCC) is Epigenetically Regulated by SET Nuclear Oncogene, a Member of the Inhibitor of Histone Acetyltransferase Complex.

Directional Migration in Esophageal Squamous Cell Carcinoma (ESCC) is Epigenetically Regulated by SET Nuclear Oncogene, a Member of the Inhibitor of Histone Acetyltransferase Complex.
Author Information (click to view)

Yuan X, Wang X, Gu B, Ma Y, Liu Y, Sun M, Kong J, Sun W, Wang H, Zhou F, Gao S,


Yuan X, Wang X, Gu B, Ma Y, Liu Y, Sun M, Kong J, Sun W, Wang H, Zhou F, Gao S, (click to view)

Yuan X, Wang X, Gu B, Ma Y, Liu Y, Sun M, Kong J, Sun W, Wang H, Zhou F, Gao S,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Neoplasia (New York, N.Y.) 2017 09 1919(11) 868-884 pii S1476-5586(17)30260-9
Abstract

Directional cell migration is of fundamental importance to a variety of biological events, including metastasis of malignant cells. Herein, we specifically investigated SET oncoprotein, a subunit of the recently identified inhibitor of acetyltransferases (INHAT) complex and identified its role in the establishment of front-rear cell polarity and directional migration in Esophageal Squamous Cell Carcinoma (ESCC). We further define the molecular circuits that govern these processes by showing that SET modulated DOCK7/RAC1 and cofilin signaling events. Moreover, a detailed analysis of the spatial distribution of RAC1 and cofilin allowed us to decipher the synergistical contributions of the two in coordinating the advancing dynamics by measuring architectures, polarities, and cytoskeletal organizations of the lamellipodia leading edges. In further investigations in vivo, we identified their unique role at multiple levels of the invasive cascade for SET cell and indicate the necessity for their functional balance to enable efficient invasion as well. Additionally, SET epigenetically repressed miR-30c expression by deacetylating histones H2B and H4 on its promoter, which was functionally important for the biological effects of SET in our cell-context. Finally, we corroborated our findings in vivo by evaluating the clinical relevance of SET signaling in the metastatic burden in mice and a large series of patients with ESCC at diagnosis, observing it’s significance in predicting metastasis formation. Our findings uncovered a novel signaling network initiated by SET that epigenetically modulated ESCC properties and suggest that targeting the regulatory axis might be a promising strategy to inhibit migration and metastasis.

Submit a Comment

Your email address will not be published. Required fields are marked *

one + 6 =

[ HIDE/SHOW ]